Linked infacebooktwitteryoutube
Datar Cancer Genetics

Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Limited

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Alzheimer

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE plc

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

Datar Cancer Genetics

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Radiogenomics: a key component of precision cancer medicine

NextEdge Admin
25 Nov 2024
4 min 58 sec
0
genomic,precision cancer,Biomarkers,molecular

Radiogenomics is an emerging interdisciplinary field that integrates imaging data (radiology) with genomic information to advance precision cancer medicine. By correlating specific imaging features with genetic and molecular profiles of tumors, radiogenomics aims to provide deeper insights into cancer behavior, prognosis, and response to therapy. Here's how radiogenomics contributes to precision oncology:

1. Understanding Tumor Biology

  • Imaging Biomarkers: Radiogenomics identifies imaging biomarkers that correlate with molecular characteristics of tumors, such as mutations, gene expression patterns, and epigenetic changes. For example, specific MRI or CT features might indicate the presence of mutations like EGFR in lung cancer or IDH in gliomas.
  • Spatial Heterogeneity: While biopsy captures a limited sample of a tumor, imaging provides a non-invasive way to study the entire tumor and its microenvironment, revealing spatial heterogeneity and molecular gradients.

2. Predicting Treatment Response

  • Radiogenomics can predict how a tumor is likely to respond to treatments, such as chemotherapy, immunotherapy, or radiation therapy. Imaging-genomics associations help in tailoring therapy regimens based on individual tumor profiles.
  • For example, in brain tumors like glioblastomas, radiogenomic markers can help determine which patients may benefit from certain therapies or predict resistance mechanisms.

3. Prognostic Value

  • Radiogenomics allows clinicians to predict outcomes more accurately by linking imaging features to prognostic genomic signatures. For instance, tumors with aggressive genomic profiles often exhibit distinct imaging patterns, which can inform risk stratification.

4. Guiding Biopsies and Monitoring Disease

  • Radiogenomics helps target biopsies to the most clinically relevant regions of a tumor, minimizing the risk of missing aggressive or actionable components.
  • It facilitates longitudinal monitoring of tumor evolution through imaging, reducing the need for repeated invasive biopsies.

5. Advancing AI and Machine Learning

  • Radiogenomics relies on advanced computational techniques, including machine learning, to analyze large datasets of imaging and genomic data. These models can identify subtle patterns and correlations that are difficult to detect manually.

Challenges and Future Directions:

  • Data Integration: Combining high-dimensional imaging and genomic data requires robust computational frameworks and collaborative efforts.
  • Standardization: Standardizing imaging protocols and genomic assays is crucial for reproducibility across institutions.
  • Validation: Radiogenomic findings must be validated in large, diverse patient cohorts.
  • Ethics and Privacy: Handling sensitive genomic and imaging data requires adherence to strict privacy standards.

Clinical Applications:

Radiogenomics is already making an impact in cancers such as:

  • Brain Cancer: Correlating imaging phenotypes with mutations (e.g., IDH mutation, MGMT methylation) in gliomas.
  • Breast Cancer: Linking mammographic density and MRI features to gene expression profiles.
  • Lung Cancer: Predicting EGFR mutations and other driver alterations from CT imaging.
  • Prostate Cancer: Utilizing MRI to infer genomic markers like PTEN loss or TMPRSS2-ERG fusions.

In conclusion, radiogenomics bridges the gap between imaging and molecular oncology, enabling a more comprehensive understanding of cancer. As technology advances, it promises to refine diagnosis, improve therapeutic decisions, and enhance patient outcomes in precision cancer medicine.